Abbott’s fourth-quarter profit falls on pharmaceutical business separation costs
Abbott has presented its fourth quarter results for 2012. The proprietary pharmaceutical sales were $5.1 billion, up 7.4%. Humira was a major contributor with sales coming in at $2.7 billion, up 23.1%.
Fourth quarter sales rose 4.4% to $10.8 billion narrowly beating the analytical estimate of $10.6 billion.